<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48482">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767428</url>
  </required_header>
  <id_info>
    <org_study_id>A1900832</org_study_id>
    <nct_id>NCT01767428</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Compare Two Formulations of Paracetamol</brief_title>
  <official_title>A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol From Two Formulations in an Indian Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>India: IEC</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacokinetic study in healthy volunteers comparing  two formulations of paracetamol
      fast release in fasted state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC (0-inf)</measure>
    <time_frame>Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve from zero and extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum plasma concentration of paracetamol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t)</measure>
    <time_frame>Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time taken to reach maximum plasma concentration of paracetamol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Fever</condition>
  <condition>Headache Disorders</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Experimental Paracetamol Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Paracetamol Tablet (500 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard paracetamol tablet (500 mg) administered with 240 mL of water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>500 mg immediate release paracetamol formulations</description>
    <arm_group_label>Experimental Paracetamol Tablet</arm_group_label>
    <arm_group_label>Standard Paracetamol Tablet (500 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18-55yrs willing to give written informed consent for
             the study

          -  BMI must be within the range 18.5 - 24.9 kg/m^2

          -  Participant with a minimum weight of 50 kg

        Exclusion Criteria:

          -  Participant with current or recurrent disease that could affect the action,
             absorption or disposition of the study medication or clinical or laboratory
             assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)

          -  Participant with known or suspected intolerance or hypersensitivity to the study
             materials

          -  Participant who are vegetarian

          -  Participant smoking more than five cigarettes a day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 10, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Headache Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
